Genentech announced that the US FDA has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab) for the treatment of thyroid eye disease (TED). The designation sets a Prescription Drug User Fee Act (PDUFA) target action date of October 15, 2026, and positions the Enspryng thyroid eye disease program as the first IL-6 receptor-targeted therapy to reach this stage of US regulatory review for the indication.
Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, developed by Japan-based Chugai Pharmaceutical and commercialized by Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY). The molecule is already approved in approximately 90 countries, including the US and EU, for neuromyelitis optica spectrum disorder (NMOSD) in aquaporin-4 antibody-positive adults — a distinct autoimmune indication that has established the molecule’s safety dataset across more than 10,000 patients.
The sBLA is supported by results from SatraGO-1 (NCT05987423) and SatraGO-2 (NCT06106828), identically designed Phase III, randomized, placebo-controlled, multicenter studies that together enrolled 258 patients across 19 countries. In SatraGO-2, 53% of patients treated with satralizumab achieved the proptosis primary endpoint at week 24, compared with 23% in the placebo arm, meeting statistical significance. In SatraGO-1, 49% of satralizumab-treated patients achieved a proptosis response versus 31% on placebo; this numerical difference did not meet statistical significance, though Genentech and Roche characterize SatraGO-1 as providing confirmatory evidence in support of the filing. Exact p-values for the primary endpoints have not been disclosed in publicly accessible sources.
Satralizumab was engineered using recycling antibody technology, which enables repeated binding to the IL-6 receptor and sustained suppression of IL-6-mediated inflammatory signaling compared with conventional monoclonal antibody formats. In TED, IL-6 is implicated in driving orbital fibroblast activation, soft tissue expansion, and the inflammatory cascade that produces proptosis, diplopia, and periorbital changes. The drug is administered subcutaneously, with a loading dose schedule followed by once-monthly maintenance injections — a format that would allow at-home self-administration if approved, distinguishing it from intravenously delivered agents in the indication.